Research programme: influenza virus vaccines - Vivaldi Biosciences

Drug Profile

Research programme: influenza virus vaccines - Vivaldi Biosciences

Alternative Names: A/H7N9 LAIV - Vivaldi Biosciences; delta-NS1 LAIV for paediatrics - Vivaldi Biosciences; Influenza A/H7N9 vaccine - Vivaldi Biosciences; Int-NS1 LAIV - Vivaldi Biosciences; VB-126

Latest Information Update: 23 Jan 2014

Price : $50

At a glance

  • Originator Vivaldi Biosciences
  • Developer National Institute of Allergy and Infectious Diseases; Vivaldi Biosciences
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza A virus H7N9 subtype; Influenza virus infections

Most Recent Events

  • 21 Jan 2014 Preclinical development is ongoing for seasonal Influenza virus infections (prevention, in the elderly) in USA
  • 21 Jan 2014 Vivaldi Biosciences establishes CRADA with the National Institute of Allergy and Infectious Diseases for the development of a vaccine against Influenza virus A/H7N9 infections
  • 21 Jan 2014 Preclinical trials in Influenza-A virus H7N9 subtype (prevention) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top